The investment planning of the domestic pharmaceutical industry is in full swing, after the Approval of 53 investments amounting to 519.28 million euros in the framework of the action "Reform of the clawback system & its offsetting with research and investment expenditure", of the National Recovery and Resilience Plan "Greece 2.0" .

These 53 projects fulfil all the conditions for participation and the eligibility conditions. 85% of them are implemented by Greek companies. The above projects are part of the plan of the Greek pharmaceutical industry. This plan provides for investments totalling €1.2 billion euro over four years. This is what the Panhellenic Association of the Pharmaceutical Industry (PEF) said in a statement.

"These investments have a unique multiplier effect on the economy, through the creation of added value that remains and is reinvested in the country. In addition, these investments reduce Greece's trade deficit. This is because the domestic production of medicine ensures that the needs are met. At the same time, employment is strengthened with permanent, skilled and well-paid new jobs", emphasizes (ECEC).

He notes that with the completion of the investment program, Greece will be able to become a European "hub" of production, research and innovation. At the same time, the phase-out of drug imports from third countries, such as China and Asia, will be completed. At the same time, domestic production will be further strengthened. In addition, exports abroad will increase, thus contributing to the reduction of the trade deficit.

Theodoros Tryfon, president of the Panhellenic Association of the pharmaceutical industry

«The Greek pharmaceutical industry actively participates in the recovery effort of the national economy. With the assistance of the three co-competent ministries and in the context of offsetting the clawback with the productive investments of the sector, investments that have multiplier benefits for society are implemented. Especially shield the health and pharmaceutical care system, ensuring market adequacy and patients' access to all necessary treatment; reducing dependence on imports, while at the same time leading to the Promotion of our country as a hub for the research and production of medicines in the wider region of SE Europe".